RCAMU
REGN icon

Rothschild & Co Asset Management US’s Regeneron Pharmaceuticals REGN Stock Holding History

Rothschild & Co Asset Management US’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,014
Closed -$498K – 516
2017
Q2 		$498K Sell
1,014
-124
-11% -$54.3K 0.01% 517
2017
Q1 		$441K Buy
+1,138
New +$422K 0.01% 540

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Rothschild & Co Asset Management US's REGN Position: Q3 2017 in Review

Rothschild & Co Asset Management US sold out of Regeneron Pharmaceuticals (REGN) in Q3 2017, closing a stake of 1,014 shares — an estimated $498K sold.

Rothschild & Co Asset Management US first reported a position in REGN in Q1 2017 and held it in 2 quarters. The position peaked at $498K in Q2 2017. 605 funds tracked by Wall St. Rank hold REGN as of Q3 2017.

  • Rothschild & Co Asset Management US reported no remaining Regeneron Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 1,014 Regeneron Pharmaceuticals shares in Q3 2017, an estimated $498K.
  • Rothschild & Co Asset Management US first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Rothschild & Co Asset Management US's Regeneron Pharmaceuticals position peaked at $498K in Q2 2017.
  • 605 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2017.

Based on Rothschild & Co Asset Management US's 13F filing for Q3 2017, filed 8 Nov 2017.